Released on = May 2, 2007, 5:49 pm

Press Release Author = Emiliem, Inc.

Industry = Biotech

Press Release Summary = The Van Andel Research Institute an independent medical
research facility known for its research into the genetic and molecular origins of
cancer and other diseases and Emiliem, Inc. a private biotechnology company focused
on the discovery and development of molecularly-targeted oncology drugs and their
companion biomarkers, announce the signing of an Agreement where Van Andel and
Emiliem will work together to translate Emiliem\'s discoveries into therapies to
conquer cancer and enhance lives. Financial details of the multi-year agreement were
not disclosed

Press Release Body = The Van Andel Research Institute an independent medical
research facility known for its research into the genetic and molecular origins of
cancer and other diseases and Emiliem, Inc. a private biotechnology company focused
on the discovery and development of molecularly-targeted oncology drugs and their
companion biomarkers, announce the signing of an Agreement where Van Andel and
Emiliem will work together to translate Emiliem\'s discoveries into therapies to
conquer cancer and enhance lives. Financial details of the multi-year agreement were
not disclosed.

\"The Van Andel Research Institute has gained worldwide recognition for research in
cancer and the discovery and implementation of biomarker strategies for
therapeutics. Implementing a translational medicine approach right from the
beginning of our research will help us to define a rational biomarker strategy for
each drug candidate and to extend this into early targeted therapy clinical trials\"
said Dale E. Johnson, Pharm.D., Ph.D., President and CEO of Emiliem. \"Validating the
response of specific cancers from patient-derived samples should lead to a rational
process where we can conduct clinical trials in patients most likely to respond to
specific multi-kinase inhibitors.\"

\"We are very excited about the innovative and streamlined approach that Emiliem
takes to drug discovery, as well as the current and future drugs in their pipeline\"
said Craig Webb, Ph.D., Director of the Program of Translational Medicine at VAI.
\"Based upon the various drugs targeted mechanisms of action, we plan to evaluate
their efficacy in conjunction with the development of a biomarker strategy that can
lead to their optimal use in patients\"


Web Site = http://www.emiliem.com/may3press.html

Contact Details = Emiliem, Inc.
6027 Christie Ave
Emeryville, CA 94608
510 923 0404 (ph)
866 803 8811 (fax)
info@emiliem.com